Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US미국에서 백신 접종을 하지 않은 가족 중 단클론 항체를 사용한 COVID-19 예방의 예상 건강 결과 및 비용Randomized Controlled Trial Published on 2022-04-012022-09-11 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Administered age Casirivimab complementary confirmed COVID-19 case Contact Coverage COVID-19 COVID-19 case COVID-19 infection COVID-19 infections COVID-19 pandemic COVID-19 vaccination death deaths disrupt effective vaccine Effective vaccines eligible Estimated Ethnicity exposure to Health health system Hospitalization hospitalizations household household contact Imdevimab IMPROVE individual Infection intensity mAb mAbs monoclonal antibodies monoclonal antibody Older outcome Postexposure Prophylaxis Probability public health randomized clinical trial reduce reduce costs Sex subcutaneous injection subcutaneous injections susceptible symptomatic infection symptomatic infections threshold thresholds Transmission Vaccination Status Vaccine variant of SARS-CoV-2 [DOI] 10.1001/jamanetworkopen.2022.8632 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant델타 변이형이 우세하기 전과 우세한 기간 동안 미군 병사들 사이에서 mRNA-1273, BNT162b2 및 JNJ-78436735 COVID-19 백신의 효과Article Published on 2022-04-012022-09-11 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Antigen B.1.617.2 BNT162b2 booster dose booster doses case-control study Chain Reaction circulation Cohort conducted confounders Control COVID-19 COVID-19 vaccination COVID-19 vaccine decrease Defense defined Delta delta variant Department Effectiveness evaluated highest Hospitalization individual individuals JNJ-78436735 Laboratory logistic regression model lowest male median age mRNA mRNA-1273 mRNA-1273 vaccine Odds ratio outcome outcomes performed polymerase chain polymerase chain reaction positive SARS-CoV-2 delta SARS-COV-2 infection SARS-CoV-2 test significantly higher significantly lower stratified Support Surveillance symptomatic infection Symptoms test result the SARS-CoV-2 vaccination Vaccine variant variants of SARS-CoV-2 [DOI] 10.1001/jamanetworkopen.2022.8071 PMC 바로가기 [Article Type] Article
A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students대학생을 대상으로 SARS-CoV-2 혈청전환 및 연쇄 바이러스 검사를 측정한 코호트 연구Article Published on 2022-03-312022-09-11 Journal: BMC Infectious Diseases [Category] MERS, SARS, 진단, 치료기술, 치료법, 치료제, [키워드] Abbott Anti-spike antibody Antibody decline Antibody Response Architect assays asymptomatic infection asymptomatic infections Cohort cohort study collected Decline detect difference examined help IgG IgG antibodies immune protection IMPROVE incidence individual Infection majority positive provided reported Result SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 serology Seroconversion seroconverted serology testing seropositive Seroprevalence serum Surveillance Symptom symptom data symptomatic infection symptomatic infections target the antibody response the SARS-CoV-2 threshold Viral was tested [DOI] 10.1186/s12879-022-07314-5 PMC 바로가기 [Article Type] Article
Communication about vaccine efficacy and COVID-19 vaccine choice: Evidence from a survey experiment in the United States백신 효능 및 COVID-19 백신 선택에 대한 커뮤니케이션: 미국에서 실시한 설문조사 실험의 증거Article Published on 2022-03-302022-09-11 Journal: PLoS ONE [Category] 변종, [키워드] Affect American asked black choice clinical trial combined efficacy communication control group COVID-19 COVID-19 vaccine criteria death defined Efficacy experiment Health Hospitalization information inoculated Latino mass vaccination Metrics mRNA mRNA vaccine offer outcome pair Pfizer/BioNTech preference reported Result significantly more Strong symptomatic symptomatic infection the United State Treatment treatment groups vaccination Vaccine vaccine efficacy Vaccine hesitancy Vaccines variants Viral vector vaccine while [DOI] 10.1371/journal.pone.0265011 PMC 바로가기 [Article Type] Article
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years – PROTECT Cohort, July 2021-February 20225-11세 아동 및 12-15세 청소년 사이에서 SARS-CoV-2 감염 예방에 2회분 BNT162b2(Pfizer BioNTech) mRNA 백신의 효과 - PROTECT 코호트, 2021년 7월-2022년 2월Article Published on 2022-03-182022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종, [키워드] 95% CI adjusted Adolescent age average B.1.1.529 B.1.617.2 BNT162b2 CDC children circulation Committee COVID-19 symptom COVID-19 symptoms COVID-19 vaccinations COVID-19 vaccine Delta demonstrated dose doses Effectiveness eligible Frequency group health information Infection laboratory-confirmed SARS-CoV-2 infection less Local location mRNA omicron participant Pfizer Pfizer-BioNTech Practice predominant Preventing prospective cohort real-world data receipt referred to SARS-CoV-2 SARS-COV-2 infection sick social contact Sociodemographic characteristics symptomatic and asymptomatic symptomatic infection Symptoms the United State United States Vaccine variant virus was tested Year [DOI] 10.15585/mmwr.mm7111e1 PMC 바로가기 [Article Type] Article
Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance예방 접종 후 경과 시간에 따른 COVID-19 예방 접종과 증상 SARS-CoV-2 감염의 연관성 및 델타 변이형 우세Article Published on 2022-03-152022-09-11 Journal: JAMA [Category] SARS, 변종, [키워드] 95% CI access Ad26 Ad26.COV2.S Adults amplification Analysis association attenuation BNT162b2 Case-control Control COVID-19 COVID-19 testing COVID-19 vaccination COVID-19 vaccine Delta delta variant dose doses Effectiveness estimate greater increase in Increasing initial measure monitoring mRNA mRNA vaccination mRNA-1273 multivariable logistic regression NAAT nucleic acid nucleic acid amplification tests Odds ratio of BNT162b2 Older outcome platform receipt SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid second dose significantly symptomatic infection symptomatic SARS-CoV-2 infection Testing time vaccination Vaccine variant white [DOI] 10.1001/jama.2022.2068 PMC 바로가기 [Article Type] Article
Divergent trajectories of antiviral memory after SARS-CoV-2 infectionArticle Published on 2022-03-102022-10-04 Journal: Nature Communications [Category] MERS, SARS, 바이오마커, 변종, 유전자 메커니즘, 진단, 치료제, [키워드] acute respiratory syndrome Alpha anti-SARS-CoV-2 antibody Antibody Response Antiviral approach Asymptomatic B cell memory B.1.1.7 B.1.351 Cohort coronavirus ELISPOT healthcare worker heterogeneity identify Immunity Immunological memory infecting Infection Integrative analysis longitudinal cohort study machine-learning memory modeling neutralising antibody participant presenting priming Protective responses robust SARS-CoV-2 SARS-COV-2 infection severe disease Spike-specific antibody subsequent symptomatic infection T cell T cell responses trajectory vaccination variant variants Victoria viral infection [DOI] 10.1038/s41467-022-28898-1 PMC 바로가기 [Article Type] Article
Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2-Seropositive Individuals중증 급성 호흡기 증후군 코로나바이러스 2-혈청 양성 개인에서 두 번째 코로나바이러스 질병 2019 유행 중 증상 감염 위험Article Published on 2022-03-092022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 진단, [키워드] 95% confidence interval analyzed antibody coronavirus disease COVID-19 Immunoglobulin individual Italian natural immunity Reinfection reinfection risk representing respiratory risk SARS-CoV-2 screened second serological Serological screening seropositive participant symptomatic infection Wave [DOI] 10.1093/cid/ciab556 PMC 바로가기 [Article Type] Article
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection증상이 있는 SARS-CoV-2 알파 감염이 있는 백신 접종 환자의 적응 면역 반응Article Published on 2022-03-082022-09-11 Journal: JCI Insight [Category] MERS, SARS, 변종, 진단, [키워드] Adaptive immunity Alpha Alpha variant antibody antibody levels Antibody titers Breakthrough infection breakthrough infections caused Cellular immune response cellular immune responses characterized Cohort COVID-19 declined defined disease ELISA Genetic variation HCs healthy control IFN-γ IgG antibody IgG antibody titers IgG titer IgG titers immune immune response immune responses infected patient infected patients Infection Infectious disease mRNA vaccination neutralization activity Neutralizing neutralizing antibody Patient protective immunity response SARS-CoV-2 SARS-CoV-2 vaccination severe disease sustained symptomatic symptomatic infection symptomatic infections symptomatic patient Symptomatic patients T cell T cell response T cell responses the SARS-CoV-2 the vaccine vaccination Viral viral variant Viral variants virus Virus neutralization virus-specific T cell [DOI] 10.1172/jci.insight.155944 PMC 바로가기 [Article Type] Article
Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents미국 청소년에 대한 BNT162b2 COVID-19 백신의 임상 효과 평가Research Published on 2022-03-032022-09-10 Journal: JAMA Network Open [Category] MERS, SARS, 변종, [키워드] 95% CI Adolescent age assessment association asymptomatic infection B.1.617.2 black BNT162b2 BNT162b2 vaccine case-control study caused Chain Reaction clinical Clinical data Clinical symptoms clinical trial conducted Connecticut Control COVID-19 COVID-19 vaccine defined Delta delta variant dose doses effective Effectiveness elapsed estimate exposure female Final finding General population Hispanic Hospitalization hospitalizations immunization immunized Importance Increases increases in Infection IQR logistic regression models matched control measure median age median time medical record medical records negative test New objective Odds ratio of BNT162b2 participant Participants Point positive test result predominant Primary outcome receiving Relevance residence Result retrospective RT-PCR RT-PCR test SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 positivity SARS-CoV-2 test secondary setting single dose symptomatic and asymptomatic symptomatic infection symptomatic infections test result test results tested the SARS-CoV-2 the vaccine Vaccine vaccine dose vaccine doses variant of SARS-CoV-2 white [DOI] 10.1001/jamanetworkopen.2022.0935 PMC 바로가기 [Article Type] Research